Q32 Bio (NASDAQ:QTTB) CEO Jodie Pope Morrison Sells 9,896 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) CEO Jodie Pope Morrison sold 9,896 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total value of $44,630.96. Following the sale, the chief executive officer directly owned 89,104 shares in the company, valued at approximately $401,859.04. This trade represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jodie Pope Morrison also recently made the following trade(s):

• On Tuesday, December 2nd, Jodie Pope Morrison sold 22,506 shares of Q32 Bio stock. The shares were sold at an average price of $3.46, for a total value of $77,870.76.

Q32 Bio Trading Down 4.2%

Q32 Bio stock opened at $4.56 on Friday. The firm has a market cap of $56.11 million, a PE ratio of -1.33 and a beta of 0.16. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $6.37. The stock’s 50 day simple moving average is $3.81 and its two-hundred day simple moving average is $2.90.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. HC Wainwright initiated coverage on Q32 Bio in a report on Wednesday. They issued a “buy” rating and a $13.00 price target for the company. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Q32 Bio currently has a consensus rating of “Hold” and an average price target of $14.00.

Q32 Bio News Summary

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Monaco Asset Management SAM grew its holdings in shares of Q32 Bio by 17.1% during the second quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock worth $882,000 after buying an additional 86,486 shares in the last quarter. Geode Capital Management LLC boosted its position in Q32 Bio by 19.9% during the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after acquiring an additional 17,617 shares during the last quarter. Renaissance Technologies LLC boosted its position in Q32 Bio by 110.6% during the fourth quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after acquiring an additional 52,300 shares during the last quarter. Jane Street Group LLC purchased a new stake in Q32 Bio during the 4th quarter valued at about $84,000. Finally, HRT Financial LP grew its stake in Q32 Bio by 66.5% during the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after acquiring an additional 9,862 shares in the last quarter. 31.32% of the stock is owned by institutional investors and hedge funds.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.